



FORWARD LOOKING STATEMENTS

Safe Harbor Statement

This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "hopes," "intends," "estimates," "expects," "projects," "plans," "look forward to," "anticipates" and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements are not guarantees of performance and actual results could differ materially from those contained in such statements. These forward-looking statements are based on our current expectations and beliefs concerning future events affecting us and involve known and unknown risks and uncertainties that may cause our actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties are discussed in greater detail in our Annual Report on Form 10-K and Quarterly Report on Form 10-Q under the caption "Risk Factors" and in other documents filed by us from time to time with the Securities and Exchange Commission. We caution you not to place undue reliance on the forward-looking statements contained in this presentation. All forward-looking statements are based on information currently available to us as of today, and we undertake no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

Health Claims Disclaimer

Statements made in this presentation and appendices have not been evaluated by the Food and Drug Administration. LifeVantage products are not intended to treat, cure, prevent or mitigate any disease. The statements in this presentation are for investors' educational purposes only.







2



THE COMPANY: LifeVantage (NASDAQ: LFVN)

LifeVantage is a pioneer in Nutrigenomics - a new science dedicated to cracking the human aging code.

We agree with leading researchers that extending human life is inevitable. However, we believe that in order to truly enjoy extreme longevity, we need to biohack both our physical and financial health. That is why we have combined our pioneering nutrigenomics efforts with a powerful entrepreneurial vehicle.

Our products are sold exclusively through that entrepreneurial vehicle - our network of independent distributors.



LifeVantage Factsheet


NASDAQ Ticker	LFVN	Share price ¹	\$4.14
Shares outstanding ¹	14.2 million	Float ¹	13.5 million
Market Capitalization ¹	\$58.6 million	Enterprise Value ¹	\$52.3 million
Average Daily Volume ¹	30,268	Fiscal 2017 Revenue	\$199.5 million
Cash at Dec 31, 2017	\$12.8 million	Fiscal 2017 Adjusted EBITDA ²	\$13.1 million
Debt at Dec 31, 2017	\$6.5 million	Fiscal 2017 Adjusted EPS ²	\$0.27

(1) As of February 12, 2018 (2) A reconciliation of non-GAAP measures is included in the appendix to this presentation Fiscal year ends June 30



4





SEPTEMBER 12, 2017

THE TODAY SHOW

"The latest trend in nutrition isn't a fad diet or newly discovered supplement; it's your DNA."

FOX NEWS

"Nutrigenomics...is changing everything. Where we once thought we were powerless is now an area over which we have at least some control. The ability to use nutrition to affect our genes means that we're no longer at the mercy of our DNA. "







PROJECTED MARKET

NUTRIGENOMICS

"Nutrigenomics market is

expected to reach

\$17,313,500,000

by 2023."

MARKET RESEARCH FUTURE



Market trends relating to specific LifeVantage products.

ANTI-AGING

Nrf2, NRF1, TrueScience Skin Care

2015: **\$140.3 bn**

2021: **\$216 bn**

SKIN CARE


TrueScience

2015: **\$121 bn**

2021: **\$154 bn**

LIFEVANTAGE

ADDITIONAL TRENDS



Sources: Statistica. Research and Markets and Stratistics MRC







TRENDS

The rise of the health activated individual

- Rapid democratization of genomic and other personalized health data is giving rise to a new wave of health-conscious individuals
- More than ever, education and understanding of one's own health is becoming widespread
- Individuals will research, measure and manage their overall health much like their personal finances
- Millennials have become a major driving force, empowered by ready access to genomic testing, health tools and a social network environment filled with influencers, all with a desire to hack the code to a healthier lifestyle

Biohacking

LifeVantage is a biohacking company. Using nutrigenomics to hack the human body for increased health.

These trends have led to the emergence of "Biohacking"

- The art of hacking your biology using nature's built-in mechanisms to stack the cards in your favor and become the best version of yourself
- Bio-hacking is using science and personalized results to take control of and upgrade your body, your mind and your life
- Our mission is to "Bio-Hack the Aging Code" through the relentless pursuit of science-based, nutrigenomic products with the intent of helping our customers live longer, healthier lives



Premium Products



Patented

Several patents, including our initial patent "Compositions And Methods For Alleviating Inflammation And Oxidative Stress In A Mammal"

Science-backed

Protandim Studies conducted at the following institutions: The Ohio State University LSU University of Colorado Denver Virginia Commonwealth University Colorado State University **Texas Tech University**

Peer-reviewed Published Research

Research published in the following medical journals: Free Radical Biology & Medicine Enzyme Research Circulation American Journal of Physiology—Lung Cellular and Molecular Physiology









HOW WE GO TO MARKET







DIRECT SELLING CHANNEL

A large global sales channel ideally suited for our products


- Global sales of \$183 billion in 2016
- CAGR of 5% since 2013
- More than 107 million direct sellers worldwide




DIRECT SELLING (US)

25


PEOPLE INVOLVED IN DIRECT SELLING *(in millions)*



US RETAIL SALES (*in billions*)



S T A T I S T I C S





13

Direct selling regional sales and top 3 product categories.

North America: \$37.8 billion

- Wellness: **34%**
- Cosmetics & Personal Care: **17%**
- Household Goods & Durables: **14%**

South & Central America: \$25.2 billion

- Cosmetics & Personal Care: **62**%
- Wellness: 21%
- Clothing & Accessories: **8%**

LIFEVANTAGE

ROOM FOR GROWTH

Western Europe: \$29.5 billion

- Wellness: **34%**
- Cosmetics & Personal Care: **16%**
- Home Improvement: **13%**

Asia-Pacific: \$84.1 billion

- Wellness: 41%
- Cosmetics & Personal Care: **29%**
- Household Goods & Durables: **13%**

Current LifeVantage Market





WHAT IS GOING TO DRIVE GROWTH?





GROWTH **OPPORTUNITIES**

Geographical Greater China expansion utilizing an e-commerce model **Opening of Germany**

Expanding Our Distributor base

New Products

Tools and Technologies







CROSS BORDER E-COMMERCE PROGRAM INTO MAINLAND CHINA

Entered Mainland China through an innovative e-commerce and social influencer model

- Formally launched on February 1, 2018 •
- Business model is not multi-level + marketing
- Utilizing third party social influencers in + China
- Products already approved for + e-commerce









EXPANDING DISTRIBUTOR BASE

RED CARPET PROGRAM

- Recently deployed an enhanced effort to attract new experienced leaders to LifeVantage through a program focused on creating relationships with developed leaders with access to our corporate leadership team, while providing activity based incentives as they build their business
- Incentivize experienced sales leaders to attract and retain accomplished salespeople to drive our business

Enhancing the demographics and skillset of our distributor base

- Focused on enhancing distributor base by attracting a second wave of leaders who are technology adept and social commerce savvy
- History of success with similar programs, which have demonstrated significant return on investment





NEW PRODUCT INTRODUCTIONS IN 2018

Vitality Stacks

- Reconfigured product strategy from single products to a regimen that creates integrated product systems
- Combining several of our powerful nutrigenomic products into a single solution that will become the basis of our biohacking protocol
 - Vitality Stack
 - Beauty Stack
- Introduced Vitality Stack Packets, providing convenient single-day serving size for on-the-go customers

Flagship Product Sent to Key Growth Markets

Recent launch of Protandim in Mexico and Thailand

New Product Launches


- Omega+
- **Protein Flavor Enhancers**
- TruScience Hand Cream





Tools and Technology

ADDITIONAL EFFORTS TO DRIVE LONG TERM GROWTH



TOOLS


Utilizing artificial intelligence and machine learning to assist our distributor base in selling and empowering them with digital technology with the Lifevantage App.







SALES HISTORY



May 2015 New CEO

• Began to implement growth initiatives

September 2016 Disruption

Review of cross border sales
resulted in policy and procedure
adjustments that interrupted sales
momentum


March 2017 Management Enhancements

- New CFO
- New COO





GLOBAL REACH



Distribution of sales by sales area.





PROGRESS ON 2018 INITIATIVES

- Formally launched in China on February 1, 2018 utilizing a new ecommerce business model leveraging independent in-market social influencers that has been specifically developed for entry into Mainland China
- Introduced the tools and training to support and integrate key messaging around our biohacking and nutrigenomics stories across our field sales force
- Launched several products: Omega+, Vitality Stack, Beauty Stack, TruScience Hand Cream, Protein Flavor Enhancers and • Vitality Stack Packets
 - Stacks, including future introductions, will become the primary protocol to support our biohacking culture
- Scheduled to complete next phase of roll-out of the LifeVantage App technology platform in mid-March
- Accelerated deployment of the Red Carpet program to attract new and experienced direct sales leaders to LifeVantage
- Began process of upgrading corporate ERP system, deploying Microsoft Dynamics 365
- Launching the Global Customer Acquisition Program in late March, further supporting our geographical expansion
- Rolling out a new customer program, whereby we can directly acquire new customers, leveraging our marketing and public relations investments
 - and be assigned a distributor after the first order

• Opening up LifeVantage.com such that new customers can come directly to LifeVantage to shop for our products






AMERICAS MARKET



75% OF SALES

- Launched Protandim NRF2 in Mexico
- Successful Canada Leadership Academy in Vancouver and Elite Academy events in Orlando










ASIA PACIFIC & EUROPE MARKETS

25% OF SALES

- Japan has turned
 - 12.9% local currency growth during Q2:2018
- Launched China on February 1st
- Launched Germany on September 1st
- Introduced NRF2 in Thailand
- Targeting Taiwan launch mid year calendar 2018
- Successful Leadership Academy in Japan, Australia, and Europe







LIFEVANTAGE **BUSINESS MODEL**

				Long-term
(as % of revenue)	FY 2015	FY 2016	FY 2017	Target
Gross Margin ¹	84.2%	83.6%	83.2%	84.0%
Commissions and Incentives	47.8%	49.9%	48.5%	48.0%
SG&A ²	29.4%	26.3%	30.6%	24.0%
Operating Margin ²	7.0%	7.3%	4.2%	12.0%
Adjusted EBITDA Margin ²	9.2%	9.5%	6.6%	14.5%

Robust gross margin and highly variable cost structure produces strong incremental margins approaching 36%

A reconciliation of non-GAAP items is included at the appendix of this presentation

¹ Non-GAAP adjustments to FY 2015 gross margin to exclude recall insurance recovery

² Non-GAAP adjustments to FY 2015 to 2017 SG&A, operating margin and adjusted EBITDA to exclude expenses associated with the Audit Committee review, class action expenses, non-recurring legal expenses, reverse split fees and recruiting, severance and management transition fees





INVESTMENT SUMMARY


Well positioned with on-trend scientific products in a growing, global sales channel

Highly efficient business model with strong cash flow and high incremental margins

Continuous focus on product innovation and international market opportunities position us for growth

Demonstrated ability to drive accelerated revenue growth





APPENDIX



Recent Operating Results Comparison

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

Revenue, net Cost of sales **Gross profit**

Commissions and incentives Selling, general and administrative Total operating expenses

Operating income

Interest expense Other income (expense), net Total other income (expense) Income before income taxes Income tax expense Net income

EPS (Net income per share, basic) EPS (Net income per share, diluted)

Weighted average shares, basic Weighted average shares, diluted

Non-GAAP Items Adjusted EBITDA* Adjusted Net Income* Adjusted EPS (Net income per share, diluted)*

C	st Recent Quarter Fiscal 2018	F	ior Year Period Fiscal 2017	Year over Year Change %
\$	49,482	\$	48,947	1.1%
	9,117		7,500	
	40,365		41,447	(2.6%)
	23,395		23,540	
	14,643		17,207	
	38,038		40,747	
	2,327		700	232.4%
	(103)		(138)	
	(169)		(150)	
	(272)		(288)	
	2,055		412	
	(1,783)		(129)	
	317		283	12.0%
\$	0.02	\$	0.02	0.0%
\$ \$	0.02	\$	0.02	0.0%
	13,956		13,840	
	14,153		14,132	
	3,662		3,855	(5.0%)
	1,610		1,594	1.0%
\$	0.11	\$	0.11	0.0%





Historical Income Statements

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)		Fisca	al Year	[.] ended Jun	ie 30,		Six	« Months ende	ed Dece	mber 31,
(In thousands, except per share data)		2015		2016		2017		2016		2017
	(as	s revised)	(as	revised)						
Revenue, net	\$	190,336	\$	206,540	\$	199,489	\$	103,841	\$	98,609
Cost of sales		28,010		33,932		33,456		16,332		17,856
Gross profit		162,326		172,608		166,033		87,509		80,753
Commissions and incentives		91,074		103,120		96,662		49,836		46,804
Selling, general and administrative		57,353		56,074		64,922		34,987		30,224
Total operating expenses		148,427		159,194		161,584		84,823		77,028
Operating income		13,899		13,414		4,449		2,686		3,725
Interest expense		(3,087)		(3,321)		(570)		(275)		(265)
Other income (expense), net		(159)		(1,409)		(969)		(321)		(147)
Total other income (expense)		(3,246)		(4,730)		(1,539)		(596)		(412)
Income before income taxes		10,653		8,684		2,910		2,090		3,313
Income tax expense		(3,528)		(2,578)		(1,302)		(627)		(2,179)
Net income		7,125		6,106		1,608		1,463		1,134
EPS (Net income per share, basic)	\$	0.51	\$	0.44	\$	0.12	\$	0.11	\$	0.08
EPS (Net income per share, diluted)	\$	0.50	\$	0.42	\$	0.11	\$	0.10	\$	0.08
Weighted average shares, basic		13,899		13,730		13,881		13,830		13,959
Weighted average shares, diluted		14,150		14,531		14,118		14,176		14,117
Non-GAAP Items										
Adjusted EBITDA*		17,436		19,650		13,087		8,203		6,324
Adjusted Net Income*		6,755		9,235		3,933		3,482		2,629
Adjusted EPS (Net income per share, diluted)*	\$	0.48	\$	0.64	\$	0.27	\$	0.24	\$	0.19





Historical Balance Sheet and Cash Flows

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

SUMMARIZED BALANCE SHEET AND CASH FLOW METRICS

(Unaudited, in thousands, except per share data)	2015
Cash and Cash Equivalents	\$ 13,9
Current Portion of Long-term Debt Long-term Debt, Net of Discount Total Debt	 11,1 9,6 20,7
Net Cash (Cash and equivalents less total Debt) Net Cash per share, diluted	\$ (6,8 (0.
Total Assets Total Stockholders' Equity Book Value per share, diluted	\$ 41,1 1,8 0 .
	I
(Unaudited, in thousands, except per share data)	2015
Net Cash Provided by Operating Activities Capital Expenditures	\$ 13,2
Free Cash Flow Free Cash Flow per share, diluted	\$ 12,0 0 .

7	-
12,794	
2,000	
4,457	
6,457	-
6,337	
0.45	
45,656	
16,505	
1.17	
	6,457 6,337 0.45 45,656 16,505

Fiscal Year ended June 30,

Six Months ended December 31,

	2016	2017	2016	2017
221	\$ 6,036	\$ 6,597	\$ 5,100	\$ 4,682
59	 562	 1,055	 237	 2,117
62	5,474	5,542	4,863	2,565
.85	\$ 0.38	\$ 0.39	\$ 0.34	\$ 0.18





Non-GAAP Reconciliations

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

Adjusted Net Income							
(Unaudited, in thousands, except per share data)		Fiscal Year		Fiscal 2017	Fiscal 2018	Fiscal 2017	Fiscal 2018
	2015	2016	2017	Q2	Q2	First Six Months	First Six Months
Period ended	6/30/15	6/30/16	6/30/17	12/31/16	12/31/17	12/31/16	12/31/17
GAAP Net income	\$7,126	\$6,106	\$1,608	\$283	\$317	\$1,463	\$1,134
Adjustments:		—	—		—		—
Recall related expenses	(2,000)	—	—		—	—	—
Executive team recruiting and transition expenses	880	928	744	65	163	65	207
Audit committee independent review expenses			2,742	1,730		2,742	
Class-action lawsuit expenses		—	170		20		216
Executive Team Severance Expenses, Net	565	632	39	79	_	79	_
Reverse Split Fees		159	_	_	_	_	_
Write-Off of Deferred Debt Offering Costs		1,544	_	_	_	_	_
Write-off of intangible assets		—	350	_	_	_	
Jenkon Write-Off		1,186	_				
Other nonrecurring legal and accounting expenses		—	160				51
Tax impact of adjustments	184	(1,320)	(1,881)	(563)	(56)	(867)	(145)
Tax expense impact of revaluation of deferred tax assets	_	_	_	_	1,166	_	1,166
Total adjustments, net of tax	(371)	3,129	2,324	1,311	1,293	2,019	1,495
Non-GAAP Net Income:	6,755	9,235	3,933	1,594	1,610	3,482	2,629
Diluted earnings per share, as reported	0.50	0.42	0.11	0.02	0.02	0.10	0.08
Total adjustments, net of tax	(0.02)	0.22	0.16	0.09	0.09	0.14	0.11
Diluted earnings per share, as adjusted	0.48	0.64	0.27	0.11	0.11	0.24	0.19





Non-GAAP Reconciliations

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

EBITDA and Adjusted EBITDA

(Unaudited, in thousands		Fiscal Year			Fiscal 2018	Fiscal 2017	Fiscal 2018
	2015	2016	2017	Q2	Q2	First Six Months	First Six Months
Period ended	6/30/15	6/30/16	6/30/17	12/31/16	12/31/17	12/31/16	12/31/17
GAAP Net income	\$7,126	\$6,106	\$1,608	\$283	\$317	\$1,463	\$1,134
Interest Expense	3,087	3,321	570	138	103	275	265
Provision for income taxes	3,527	2,578	1,302	129	1,738	627	2,179
Depreciation and amortization	2,285	1,895	1,643	414	322	826	672
Non-GAAP EBITDA:	16,025	13,900	5,123	964	2,480	3,191	4,250
Adjustments:							
Stock compensation expense	1,806	2,621	2,647	576	830	1,515	1,453
Other (income) expense, net	159	1,409	969	150	169	321	147
Other adjustments	(554)	1,720	4,348	2,165	183	3,176	474
Total adjustments	1,411	5,750	7,964	2,891	1,182	5,012	2,074
Non-GAAP Adjusted EBITDA	17,436	19,650	13,087	3,855	3,662	8,203	6,324



